328 related articles for article (PubMed ID: 27465265)
21. [The efficacy and safety of pioglitazone hydrochloride in combination with sulphonylureas and metfomin in the treatment of type 2 diabetes mellitus a 12-week randomized multi-centres placebo-controlled parallel study].
Pan C; Gao Y; Gao X; Li G; Luo B; Shi H; Tian H; Jia P; Lin H; Xing X; Zhao Y; Zhou L
Zhonghua Nei Ke Za Zhi; 2002 Jun; 41(6):388-92. PubMed ID: 12137601
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes.
Eguchi K; Tomizawa H; Ishikawa J; Hoshide S; Numao T; Fukuda T; Shimada K; Kario K
Hypertens Res; 2007 Jan; 30(1):23-30. PubMed ID: 17460368
[TBL] [Abstract][Full Text] [Related]
23. Effects of Pioglitazone for Secondary Stroke Prevention in Patients with Impaired Glucose Tolerance and Newly Diagnosed Diabetes: The J-SPIRIT Study.
Tanaka R; Yamashiro K; Okuma Y; Shimura H; Nakamura S; Ueno Y; Tanaka Y; Miyamoto N; Tomizawa Y; Nakahara T; Furukawa Y; Watada H; Kawamori R; Hattori N; Urabe T
J Atheroscler Thromb; 2015; 22(12):1305-16. PubMed ID: 26269002
[TBL] [Abstract][Full Text] [Related]
24. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Derosa G; Maffioli P; Ferrari I; Mereu R; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Salvadeo SA
Horm Metab Res; 2010 Aug; 42(9):663-9. PubMed ID: 20560108
[TBL] [Abstract][Full Text] [Related]
25. The IRIS (Insulin Resistance Intervention after Stroke) trial: A new perspective on pioglitazone.
Inzucchi SE; Furie KL
J Diabetes; 2016 Sep; 8(5):607-9. PubMed ID: 27125599
[No Abstract] [Full Text] [Related]
26. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.
Charbonnel BH; Matthews DR; Schernthaner G; Hanefeld M; Brunetti P;
Diabet Med; 2005 Apr; 22(4):399-405. PubMed ID: 15787663
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance.
Spence JD; Viscoli C; Kernan WN; Young LH; Furie K; DeFronzo R; Abdul-Ghani M; Dandona P; Inzucchi SE
Diabetes Obes Metab; 2022 Jun; 24(6):1150-1158. PubMed ID: 35253334
[TBL] [Abstract][Full Text] [Related]
28. Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan.
Yamasaki Y; Kawamori R; Wasada T; Sato A; Omori Y; Eguchi H; Tominaga M; Sasaki H; Ikeda M; Kubota M; Ishida Y; Hozumi T; Baba S; Uehara M; Shichiri M; Kaneko T
Tohoku J Exp Med; 1997 Nov; 183(3):173-83. PubMed ID: 9550126
[TBL] [Abstract][Full Text] [Related]
29. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
Kovacs CS; Seshiah V; Swallow R; Jones R; Rattunde H; Woerle HJ; Broedl UC;
Diabetes Obes Metab; 2014 Feb; 16(2):147-58. PubMed ID: 23906415
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.
Sabatine MS; Leiter LA; Wiviott SD; Giugliano RP; Deedwania P; De Ferrari GM; Murphy SA; Kuder JF; Gouni-Berthold I; Lewis BS; Handelsman Y; Pineda AL; Honarpour N; Keech AC; Sever PS; Pedersen TR
Lancet Diabetes Endocrinol; 2017 Dec; 5(12):941-950. PubMed ID: 28927706
[TBL] [Abstract][Full Text] [Related]
31. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
32. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.
Hu K; Xu W; Williams Z
N Engl J Med; 2016 Aug; 375(7):703-4. PubMed ID: 27532848
[No Abstract] [Full Text] [Related]
33. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.
Doehner W; Anker SD
N Engl J Med; 2016 Aug; 375(7):703. PubMed ID: 27532847
[No Abstract] [Full Text] [Related]
34. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.
Bursztyn M
N Engl J Med; 2016 Aug; 375(7):702-3. PubMed ID: 27532846
[No Abstract] [Full Text] [Related]
35. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.
Viscoli CM; Kernan WN; Young LH
N Engl J Med; 2016 Aug; 375(7):704. PubMed ID: 27532845
[No Abstract] [Full Text] [Related]
36. A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW study.
Tripathy D; Cobb JE; Gall W; Adam KP; George T; Schwenke DC; Banerji M; Bray GA; Buchanan TA; Clement SC; Henry RR; Kitabchi AE; Mudaliar S; Ratner RE; Stentz FB; Reaven PD; Musi N; Ferrannini E; DeFronzo RA
J Clin Endocrinol Metab; 2015 May; 100(5):1855-62. PubMed ID: 25603459
[TBL] [Abstract][Full Text] [Related]
37. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.
Erdmann E; Dormandy JA; Charbonnel B; Massi-Benedetti M; Moules IK; Skene AM;
J Am Coll Cardiol; 2007 May; 49(17):1772-80. PubMed ID: 17466227
[TBL] [Abstract][Full Text] [Related]
38. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
[TBL] [Abstract][Full Text] [Related]
39. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
Miyazaki Y; DeFronzo RA
Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
[TBL] [Abstract][Full Text] [Related]
40. A pilot study suggests that the G/G genotype of resistin single nucleotide polymorphism at -420 may be an independent predictor of a reduction in fasting plasma glucose and insulin resistance by pioglitazone in type 2 diabetes.
Makino H; Shimizu I; Murao S; Kondo S; Tabara Y; Fujiyama M; Fujii Y; Takada Y; Nakai K; Izumi K; Ohashi J; Kawamura R; Yamauchi J; Takata Y; Nishida W; Hashiramoto M; Onuma H; Osawa H
Endocr J; 2009; 56(9):1049-58. PubMed ID: 19738363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
